Journal: Journal for Immunotherapy of Cancer

Article Title: BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1

doi: 10.1136/jitc-2023-008303

Figure Lengend Snippet: Summary of butyrophilin 1A1 staining results in tissue microarray scores for patients with different solid and hematological tumor types

Article Snippet: Squamous non-small cell lung cancer , AMSBIO LC1921c , 84% , 10% , 6%.

Techniques: Staining, Microarray

Journal: Journal of Medicinal Chemistry

Article Title: Structure-Based Design of Potent Bcl-2/Bcl-xL Inhibitors with Strong in Vivo Antitumor Activity

doi: 10.1021/jm300608w

Figure Lengend Snippet: Figure 7. (A) Representative cell growth inhibition of 12, 14, 15, and 1 in three small-cell lung cancer cell lines. (B) Cell death induction by 12, 14, 15, and 1 in H146 cell line. Cells were treated for 24 h, and cell death was analyzed by trypan blue assay. (C) Induction of cleavage of PARP and caspase-3 in H146 cell line by 12, 14, 15, and 1. Cells were treated for 24 h, and caspase-3 (Cas 3) and PARP were probed by Western blotting: Cl PARP, cleaved PARP; Cl Cas 3, cleaved caspase-3. GAPDH was used as the loading control.

Article Snippet: These assays were performed as previously described.17 Human smallcell lung cancer cell lines H146 and H1417 were purchased from American Type Culture Collection (ATCC) and were maintained in dx.doi.org/10.1021/jm300608w | J. Med.

Techniques: Inhibition, Western Blot, Control

Journal: Journal of Medicinal Chemistry

Article Title: Structure-Based Design of Potent Bcl-2/Bcl-xL Inhibitors with Strong in Vivo Antitumor Activity

doi: 10.1021/jm300608w

Figure Lengend Snippet: Figure 8. Analysis of cytochrome c (Cyto c) release from mitochondria into cytosol and cleavage of PARP (Cl PARP) induced by 14 and 15 in H146 cells in 2 h. GAPDH was used as the loading control.

Article Snippet: These assays were performed as previously described.17 Human smallcell lung cancer cell lines H146 and H1417 were purchased from American Type Culture Collection (ATCC) and were maintained in dx.doi.org/10.1021/jm300608w | J. Med.

Techniques: Control

Journal: Journal of Medicinal Chemistry

Article Title: Structure-Based Design of Potent Bcl-2/Bcl-xL Inhibitors with Strong in Vivo Antitumor Activity

doi: 10.1021/jm300608w

Figure Lengend Snippet: Figure 9. Analysis of induction of cleavage of PARP and caspase-3 in the H146 xenograft tumor tissues by 14 (25 mg/kg, iv). Mice bearing H146 xenograft tumors were dosed with either 14 or vehicle. Animals were sacrificed at 3, 6, and 24 h time points, and tumor tissues were analyzed by Western blot for cleavage of PARP (Cl PARP) and caspase-3 (Cl caspase-3). GAPDH was used as the loading control.

Article Snippet: These assays were performed as previously described.17 Human smallcell lung cancer cell lines H146 and H1417 were purchased from American Type Culture Collection (ATCC) and were maintained in dx.doi.org/10.1021/jm300608w | J. Med.

Techniques: Western Blot, Control

Journal: Journal of Medicinal Chemistry

Article Title: Structure-Based Design of Potent Bcl-2/Bcl-xL Inhibitors with Strong in Vivo Antitumor Activity

doi: 10.1021/jm300608w

Figure Lengend Snippet: Figure 10. Antitumor activity of compound 14 in H146 xenograft model. H146 tumor cells were injected subcutaneously into SCID mice, and treatments started when tumors reached a mean volume of 70 mm3. Each group consisted of eight mice/tumors.

Article Snippet: These assays were performed as previously described.17 Human smallcell lung cancer cell lines H146 and H1417 were purchased from American Type Culture Collection (ATCC) and were maintained in dx.doi.org/10.1021/jm300608w | J. Med.

Techniques: Activity Assay, Injection

Journal: Molecular Cancer Therapeutics

Article Title: OBI-992, a Novel TROP2-Targeted Antibody–Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models

doi: 10.1158/1535-7163.MCT-24-0588

Figure Lengend Snippet: TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; SCLC, small cell lung carcinoma; TNBC, triple-negative breast carcinoma.

Article Snippet: Up to 448 formalin-fixed, paraffin-embedded human late-stage tumor tissue samples, representing 19 cancer types [bladder cancer, cervical adenocarcinoma, cervical squamous cell carcinoma (SCC), colorectal cancer, endometrial cancer, esophageal cancer, gallbladder cancer, gastric cancer, head and neck cancer, hormone receptor-positive (HR + ) breast cancer, human epidermal growth factor receptor 2-positive (HER2 + ) breast cancer, non-small cell lung cancer (NSCLC) adenocarcinoma, NSCLC SCC, ovarian adenocarcinoma, pancreatic cancer, prostate cancer, renal cell carcinoma (RCC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC)], were purchased from AMS Biotechnology.

Techniques: Expressing, Membrane, Immunohistochemistry